Lundbeck initiates clinical phase II trials with Lu AE58054 as augmentation treatment in Alzheimer's disease
Lu AE58054 is a potent and selective 5-HT6-receptor antagonist. The 5-HT6-receptor is primarily found in areas of the brain involved in cognition. A number of early trials have demonstrated that a 5-HT6-receptor antagonist could offer potential in the treatment of disorders such as Alzheimer's disease and schizophrenia and in November 2008 Lundbeck initiated a 12 week clinical phase II trial in schizophrenia. The present study examines the possible benefit of Lu AE58054 over a much longer period in Alzheimer's disease.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.